{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:00:53Z","timestamp":1776855653856,"version":"3.51.2"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.bmcl.2019.02.029","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T12:24:10Z","timestamp":1551270250000},"page":"1099-1105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of TLR7 agonistic imidazoquinoline as immunochemotherapeutic agent against P. Berghei ANKA infected rodent host"],"prefix":"10.1016","volume":"29","author":[{"given":"Ruchika","family":"Saroa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepender","family":"Kaushik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Upma","family":"Bagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhbir","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak B.","family":"Salunke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2019.02.029_b0005","unstructured":"World Health Organization. Q&A on the phase 3 trial results for malaria vaccine RTS, S\/AS01; 2017."},{"key":"10.1016\/j.bmcl.2019.02.029_b0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1203\/PDR.0b013e3181eee738","article-title":"Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome","volume":"68","author":"Idro","year":"2010","journal-title":"Pediatr Res"},{"key":"10.1016\/j.bmcl.2019.02.029_b0015","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1084\/jem.20020128","article-title":"Locally up-regulated lymphotoxin alpha, not systemic tumor necrosis factor alpha, is the principle mediator of murine cerebral malaria","volume":"195","author":"Engwerda","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmcl.2019.02.029_b0020","unstructured":"World Health Organization. Guidelines for the Treatment of Malaria; 2017."},{"key":"10.1016\/j.bmcl.2019.02.029_b0025","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3201\/eid1405.071601","article-title":"Declining artesunate-mefloquine efficacy against falciparum malaria on the cambodia\u2013thailand border","volume":"14","author":"Wongsrichanalai","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.bmcl.2019.02.029_b0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.actatropica.2011.02.016","article-title":"Malaria in the greater mekong subregion: heterogeneity and complexity","volume":"121","author":"Cui","year":"2012","journal-title":"Acta Trop"},{"key":"10.1016\/j.bmcl.2019.02.029_b0035","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-3156.2005.01429.x","article-title":"Efficacy of combination therapy with artesunate plus amodiaquine compared to monotherapy with chloroquine, amodiaquine or sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum in Afghanistan","volume":"10","author":"Durrani","year":"2005","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.bmcl.2019.02.029_b0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1473-3099(15)00320-5","article-title":"Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial","volume":"16","author":"Phyo","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"9502","key":"10.1016\/j.bmcl.2019.02.029_b0045","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(05)67669-6","article-title":"Duration of protection with RTS, S\/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial","volume":"366","author":"Alonso","year":"2005","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bmcl.2019.02.029_b0050","unstructured":"https:\/\/www.nature.com\/news\/malaria-vaccine-gives-disappointing-results-1.11785, https:\/\/brightthemag.com\/stop-celebrating-the-malaria-vaccine-that-hasnt-proven-itself-5d21b4ed57ca."},{"key":"10.1016\/j.bmcl.2019.02.029_b0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1128\/IAI.67.2.513-519.1999","article-title":"Therapy with a combination of low doses of interleukin 12 and chloroquine completely cures blood-stage malaria, prevents severe anemia, and induces immunity to reinfection","volume":"67","author":"Mohan","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.bmcl.2019.02.029_b0060","first-page":"272","article-title":"Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: promising treatments for this neglected disease Front","author":"Roatt","year":"2014","journal-title":"Immunol 5"},{"key":"10.1016\/j.bmcl.2019.02.029_b0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1046\/j.1365-2443.2001.00458.x","article-title":"Roles of toll-like receptors in innate immune responses","volume":"6","author":"Takeda","year":"2001","journal-title":"Genes Cells"},{"key":"10.1016\/j.bmcl.2019.02.029_b0070","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1128\/IAI.00923-13","article-title":"Toll-like receptor 7 mediates early innate immune responses to malaria","volume":"81","author":"Baccarella","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.bmcl.2019.02.029_b0075","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/IAI.00974-08","article-title":"Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod","volume":"77","author":"Othoro","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.bmcl.2019.02.029_h0080","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4049\/jimmunol.174.3.1259","article-title":"Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8","volume":"174","author":"Gorden","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2019.02.029_h0085","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/sj.onc.1210913","article-title":"TLR7 and TLR8 as targets in cancer therapy","volume":"27","author":"Schon","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bmcl.2019.02.029_h0090","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fcimb.2017.00324","article-title":"Cytokines and chemokines in cerebral malaria pathogenesis","volume":"7","author":"Dunst","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"10.1016\/j.bmcl.2019.02.029_h0095","first-page":"1145","article-title":"Cytokines in the pathogenesis of and protection against malaria","volume":"9","author":"Angulo","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"issue":"11","key":"10.1016\/j.bmcl.2019.02.029_b0090","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1128\/AAC.48.11.4075-4083.2004","article-title":"Chloroquine resistance in plasmodium vivax","volume":"48","author":"Baird","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.bmcl.2019.02.029_b0095","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3109\/13880209.2016.1155626","article-title":"Evaluation of herbal antimalarial MAMA decoction-amodiaquine combination in murine malaria model","volume":"54","author":"Adepiti","year":"2016","journal-title":"Pharm Biol"},{"issue":"1","key":"10.1016\/j.bmcl.2019.02.029_b0100","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12936-017-1853-5","article-title":"Antiplasmodial activity of Indigofera spicata root extract against Plasmodium berghei infection in mice","volume":"16","author":"Birru","year":"2017","journal-title":"Malar J"},{"issue":"7","key":"10.1016\/j.bmcl.2019.02.029_b0105","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1128\/AAC.01566-10","article-title":"In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine","volume":"55","author":"Pereira","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2019.02.029_b0110","first-page":"1","article-title":"Toll-like receptors and malaria \u2013 sensing and susceptibility","volume":"2","author":"Eriksson","year":"2013","journal-title":"J Trop Dis"},{"key":"10.1016\/j.bmcl.2019.02.029_b0115","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/cmi.2012.38","article-title":"TLR8: the forgotten relative revindicated","volume":"9","author":"Cervantes","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.bmcl.2019.02.029_b0120","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4049\/jimmunol.174.3.1259","article-title":"Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8","volume":"174","author":"Gorden","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2019.02.029_b0125","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1073\/pnas.0913291107","article-title":"Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA","volume":"107","author":"Martinez","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2019.02.029_b0135","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm100358c","article-title":"Structure-activity relationships in human Toll-like receptor 7-active imidazoquinoline analogues","volume":"53","author":"Shukla","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.02.029_b0140","series-title":"Immunology of Infection","first-page":"189","article-title":"In vitro analysis isolation and preparation of lymphocytes from infected animals","author":"Czuprynski","year":"1998"},{"key":"10.1016\/j.bmcl.2019.02.029_b0145","first-page":"229","article-title":"CD4+T cells expansion in P. berghei (NK-65) infected and immunized BALB\/C mice","volume":"5","author":"Kumar","year":"2015","journal-title":"J Clin Exp Pathol"},{"issue":"2","key":"10.1016\/j.bmcl.2019.02.029_b0150","doi-asserted-by":"crossref","first-page":"968","DOI":"10.4049\/jimmunol.1200688","article-title":"IFN-gamma-producing CD4+ T cells promote experimental cerebral malaria by modulating CD8+ T cell accumulation within the brain","volume":"189","author":"Villegas-Mendez","year":"2012","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.bmcl.2019.02.029_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006022","article-title":"CD8(+) T cells induce fatal brainstem pathology during cerebral malaria via luminal antigen-specific engagement of brain vasculature","volume":"12","author":"Swanson","year":"2016","journal-title":"PLoS Pathog"},{"issue":"4","key":"10.1016\/j.bmcl.2019.02.029_b0160","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ni1180","article-title":"Mechanisms of suppression by suppressor T cells","volume":"6","author":"von Boehmer","year":"2005","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.bmcl.2019.02.029_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022434","article-title":"The spleen CD4+ T Cell response to blood-stage plasmodium chabaudi malaria develops in two phases characterized by different properties","volume":"6","author":"Muxel","year":"2011","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.bmcl.2019.02.029_b0170","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1128\/iai.64.2.535-541.1996","article-title":"A Th1-associated increase in tumor necrosis factor alpha expression in the spleen correlates with resistance to blood-stage malaria in mice","volume":"64","author":"Jacobs","year":"1996","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.bmcl.2019.02.029_b0175","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/1521-4141(200006)30:6<1646::AID-IMMU1646>3.0.CO;2-0","article-title":"Involvement of IFN-gamma receptor-medicated signaling in pathology and anti-malarial immunity induced by Plasmodium berghei infection","volume":"30","author":"Amani","year":"2000","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.bmcl.2019.02.029_b0180","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4049\/jimmunol.180.2.1217","article-title":"Chemokine gene expression during fatal murine cerebral malaria and protection due to CXCR3 deficiency","volume":"80","author":"Miu","year":"2008","journal-title":"J Immunol"},{"issue":"671","key":"10.1016\/j.bmcl.2019.02.029_b0185","article-title":"CD4 T-cell subsets in malaria: TH1\/TH2 revisited","volume":"5","author":"Perez-Mazliah","year":"2015","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.bmcl.2019.02.029_b0190","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0962-8924(01)02064-5","article-title":"Signal transduction by tumor necrosis factor and its relatives","volume":"11","author":"Baud","year":"2001","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.bmcl.2019.02.029_b0195","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ijpara.2007.01.004","article-title":"Regulatory CD4+CD25+ Foxp3+ T cells expand during experimental Plasmodium infection but do not prevent cerebral malaria","volume":"37","author":"Vigario","year":"2007","journal-title":"Int J Paraitol"}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19301131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19301131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:29:02Z","timestamp":1760772542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X19301131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0960894X19301131"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.02.029","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of TLR7 agonistic imidazoquinoline as immunochemotherapeutic agent against P. Berghei ANKA infected rodent host","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}